0.3600USD0.00%Mkt Cap: 2.73M USDP/E: —Last update: 2026-05-26
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap2.73M USD
Enterprise Value8.04M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-6.00M USD
Revenue/Share—
Last Price0.3600 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees10
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS29014R2022
Valuation
P/E (Trailing)—
P/E (Forward)-0.48
PEG1.85
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.23
EPS (TTM)-0.12
EPS (Forward)-0.71
52W Range
0.000048% of range0.7501
52W High0.7501 USD
52W Low0.0000 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE50.35%
ROA-113.76%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.33M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt5.46M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.08
Current Ratio0.53
Quick Ratio0.40
Book Value/Sh-1.4950 USD
Cash/Share0.8400 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateDec 20, 2017
Splits
Last Split1:40
Split DateDec 2, 2022
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.7.57M
Float4.60M
Insiders37.36%
Institutions21.34%
Short Interest
Short Ratio0.7d
Short % Float0.80%
Short % Out.0.70%
Shares Short21.48K
Short (prev mo.)33.78K
Technical
SMA 500.1256 (+186.7%)
SMA 2000.0315 (+1044.2%)
Beta-151142.55
S&P 52W Chg28.31%
Avg Vol (30d)23.94K
Avg Vol (10d)60.63K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—